title: Change in serum lipids after acute coronary syndromes: secondary analysis of SPACE ROCKET study data and a comparative literature review.
abstract: BACKGROUND
  It has long been an accepted belief that serum cholesterol significantly falls after myocardial infarction and that a return to pre-event levels takes approximately 3 months. The magnitude and clinical significance of this fall has recently been challenged.
  
  
  METHODS
  In the Secondary Prevention of Acute Coronary Events-Reduction Of Cholesterol to Key European Targets (SPACE ROCKET) trial, we measured serum lipids of individuals on day 1 and between days 2 and 4 after acute myocardial infarction (AMI). Second, we performed a thorough literature review and compared all studies reporting data on absolute changes in lipids immediately after AMI, using weighted means.
  
  
  RESULTS
  Of 1263 SPACE ROCKET participants, 128 had paired lipid measurements where both samples had been measured using identical methods at baseline and on days 2-4 after AMI. The mean lowering in total cholesterol between day 1 and day 2-4 was 0.71 mmol/L (95% CI 0.58-0.84; P < 0.0001) and in triglycerides was 0.10 mmol/L (-0.14-0.33; P = 0.405). A total of 25 papers showing absolute lipid changes post-AMI were identified. The combined data demonstrated a mean fall in total cholesterol of 9% to 11% from baseline over days 3-14 post-AMI, whereas for triglycerides, there was a rise of 18% from baseline to between day 9 and 12 weeks.
  
  
  CONCLUSIONS
  After a secondary analysis of SPACE ROCKET data and a comparison of previously published data, we report a 10% fall in total cholesterol after AMI-a difference that is of high clinical significance. Consequently, measurement of serum lipids in patients with AMI should be performed within the first hours after presentation.
authors: Clinical Biochemistry, Leeds General Infirmary, Leeds, United Kingdom. julian.barth@leedsth.nhs.uk
authors: Julian H
authors: JH
authors: Barth
authors: Beryl M
authors: BM
authors: Jackson
authors: Amanda J
authors: AJ
authors: Farrin
authors: Maria
authors: M
authors: Efthymiou
authors: Gillian
authors: G
authors: Worthy
authors: Joanne
authors: J
authors: Copeland
authors: Kristian M
authors: KM
authors: Bailey
authors: Simon P R
authors: SP
authors: Romaine
authors: Anthony J
authors: AJ
authors: Balmforth
authors: Terry
authors: T
authors: McCormack
authors: Andrew
authors: A
authors: Whitehead
authors: Marcus D
authors: MD
authors: Flather
authors: Jane
authors: J
authors: Nixon
authors: Alistair S
authors: AS
authors: Hall
mesh_terms: D002784:Cholesterol / Q000097:blood; D005464:Fluorobenzenes / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D011743:Pyrimidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000068718:Rosuvastatin Calcium; D019821:Simvastatin / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
chemical_list: D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011743:Pyrimidines; D013449:Sulfonamides; D014280:Triglycerides; D000068718:Rosuvastatin Calcium; D002784:Cholesterol; D019821:Simvastatin